Bordetella pertussis Antibodies by Immunoblot
Whooping cough
Test Codes
ARUP: 2004328, EPIC: LAB5955, Beaker: XBRDA
Specimen Collection Criteria
Collect (preferred specimen): One Gold-top SST tube.
Physician Office/Draw Specimen Preparation
Let specimen clot 30-60 minutes then centrifuge to separate serum from cells within two hours of collection. Transfer serum to plastic transport tube and refrigerate (2-8°C or 36-46°F).
Preparation for Courier Transport
Transport: 1.0 mL serum, refrigerated (2-8°C or 36-46°F). (Minimum: 0.2 mL)
Rejection Criteria
Specimens not collected and processed as indicated.
In-Lab Processing
Let specimen clot 30-60 minutes then centrifuge to separate serum from cells within two hours of collection. Transfer serum to plastic transport tube and refrigerate (2-8°C or 36-46°F).
Transport: 1.0 mL serum, refrigerated (2-8°C or 36-46°F). (Minimum: 0.2 mL)
Storage
Specimen Stability for Testing:
Room Temperature (20-26°C or 68-78.8°F): 48 hours
Refrigerated (2-8°C or 36-46°F): 14 days
Frozen (-20°C/-4°F or below): 1 year
Specimen Storage in Department Prior to Disposal:
Specimen retention time is determined by the policy of the reference laboratory. Contact the Send Outs Laboratory with any questions.
Laboratory
Sent to ARUP Laboratories, Salt Lake City, UT.
Performed
Tuesday, Friday.
Results available in 2-6 days.
Reference Range
By report.
Test Methodology
Qualitative Immunoblot.
Interpretation
Detectable levels of IgG antibodies to B. pertussis may be seen in the serum of vaccinated individuals of all ages, in early infancy as the result of placental transfer, and in the convalescent phase of a recent infection. IgG antibodies can only be used to diagnose active infection when paired sera are available and a rise in antibody level can be demonstrated. A significant rise may not always be demonstrated as peak levels of IgG may be reached before the first sample is collected. Therefore, IgA and IgM antibody levels should be measured to diagnose active disease.
Clinical Utility
These tests are used in the serological diagnosis of B. pertussis infections.
Clinical Disease
Pertussis presents with a mild upper respiratory infection that can progress to a severe cough with a characteristic whoop that is followed by vomiting. Fever may be absent or minimal. Pertussis may last from 6 to 10 weeks in uncomplicated cases. This disease is particularly severe in the children less than one year old (1).
Epidemiology
Humans are the only known hosts of B. pertussis. In the U.S., adolescents and adults are the major sources of pertussis. Widespread active immunization for pertussis in the U.S. has lowered the morbidity and mortality rates. Pertussis can occur at any age but it is most often diagnosed in young children. Thirty-eight percent of the cases reported to the CDC occurred in infants younger than 6 months; 71% occur in children younger than 5 years (1).
Incubation Period
6 to 20 days, usually 7 to 10 days (1).
Transmission
Occurs by close contact via respiratory secretions. Up to 90% of non-immune household contacts acquire the disease (1).
Reference
- American Academy of Pediatrics. Pertussis. In: Peter G, ed. (1994) Red Book: Report of the Committee on Infectious Diseases. 23rd ed. Elk Grove Village, IL: American Academy of Pediatrics; 1994:355-367.
CPT Codes
86615 x3.
Contacts
Send Outs Laboratory – RO
248-551-9045
Name: Send Outs Laboratory – RO
Location:
Phone: 248-551-9045
Last Updated
11/12/2020
Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.